Cardiovascular pharmacotherapy in year in 2025 - PubMed
5 hours ago
- #clinical trials
- #drug approval
- #pharmacotherapy
- Four new drugs were approved: aficamten, etripamil, lerodalcibep, and plozasiran.
- Label expansions occurred for five already approved drugs.
- Results from major randomized clinical trials included both positive and neutral/negative outcomes.
- Andexanet-alfa was withdrawn from the U.S. market due to safety concerns.
- Promising experimental cardiovascular drugs are in ongoing phase 2 and 3 trials.